TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT04245397: Study of SX-682 Alone and in Combination With Oral or Intravenous Decitabine in Subjects With Myelodysplastic Syndrome

Sponsor: Syntrix Biosystems, Inc. · Phase: PHASE1 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 151 pts

Competing Trials Overlap

6 Active Trials

Excess Burn Exposure

$1,828,656

Rescue Site Savings

+$1,196,528

Unlock Full NCT04245397 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT04245397 Rescue Dossier →